Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study.
- DOI
- 10.1111/dom.71534
- Published
- 2026 Nov 9
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.71534,
title = {Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study.},
author = {Labate AM and Villari P},
year = {2026},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.71534},
url = {https://doi.org/10.1111/dom.71534}
}RIS
TY - JOUR TI - Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study. AU - Labate AM AU - Villari P PY - 2026 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.71534 UR - https://doi.org/10.1111/dom.71534 ER -
APA
AM, L., & P, V. (2026). Two-Year Trajectories of DIAL2-Predicted Cardiovascular Risk After Initiation of Semaglutide, Empagliflozin or Their Combination: The DIAL-STEP Study.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.71534
Source records
- pubmed · retrieved 2026-11-10T06:34:51.210Z